Factors Affecting BAT Activation in PET/CT

Trial Title: Factors Affecting BAT Activation in PET/CT

NCT ID: NCT05577299

Condition: Factors Affecting BAT Activation in PET/CT

Study type: Observational

Overall status: Not yet recruiting

Study design:

Time perspective: Retrospective

Intervention:

Intervention type: Device
Intervention name: PET/CT
Description: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FFDG PET/CT) is a non-invasive imaging modality used for staging and surveillance of various types of malignancies through imaging of glucose metabolism in cancer cells.

Summary: The aim of the present study is to evaluate the factors affecting BAT activation in 18F-FDG-PET/CT in different tumours

Detailed description: Positron emission tomography (PET)/CT with fluorine-18 fluorodeoxyglucose (18F-FDG) is currently a standard diagnostic tool for identifying tumours and their metastases as well as infectious or inflammatory lesions.1-3 High physiological uptake of 18F-FDG is found in organs with high glucose metabolism, such as the brain and heart. One particular tissue with high 18F-FDG uptake that can interfere with scan interpretation is brown fat.4 Brown fat, or brown adipose tissue (BAT), is involved in non-shivering thermogenesis and creates heat through glucose metabolism. It is found mostly in the cervical, supraclavicular and thoracic paravertebral regions,5 and some is also found in the axillae, mediastinum and abdomen.6 Although it is usually simple for nuclear medicine physicians to recognize BAT uptake through its typical pattern and from the low attenuation in the CT scan, high uptake in BAT can still be mistaken for a malignant lesion or cause false-negative results by obscuring small metastases and decrease diagnostic confidence of the scan professional reading. BAT has a preferential distribution over the body and a preferential occurrence in female, younger and thinner patients. It mainly interferes with scan interpretation in tumours that occurs at younger age and is located in or metastasize to the head, neck and peri clavicular/axillary regions, such as melanoma of the upper body, breast cancer, and head and neck cancers, but it can also cause problems in lung and other cancers.7.8

Criteria for eligibility:

Study pop:
cancer patients undergoing PET/CT

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: - This study will include all patients presented with different types of tumors. - patients conscious to provide informed consent Exclusion Criteria: - • Patients who have contraindications to PET/CT scanning such as: a blood glucose level higher than 150-200 mg/dL, uncontrolled diabetics. - Intolerance of PET/CT due to claustrophobia will be excluded from the study. - Patients under age of 18

Gender: All

Minimum age: 18 Years

Maximum age: 80 Years

Start date: November 1, 2022

Completion date: October 1, 2025

Lead sponsor:
Agency: Assiut University
Agency class: Other

Source: Assiut University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05577299